access

News

NICE backs Biogen's Vumerity for multiple sclerosis

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the d

News

Drugmakers pledge shorter launch times for drugs in EU

Pharmaceutical companies have said they will try to carve months off the time between approval and launch for new medicines in Europe, and reduce disparities in access between countries.

News

NICE verdict on Trodelvy threatens unequal access to drug in...

In draft guidance, NICE has said it cannot recommend Gilead Sciences' Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK.

News

NHS grants fast-track access to Takeda's lung cancer drug Ex...

Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks.

News

Moderna squares off with US government over COVID jab patent

After being hailed as a triumph of public-private drug development, Moderna's partnership with the US government on its COVID-19 vaccine looks like it may descend into acrimony.

News

Cautious welcome as NICE backs Forxiga for chronic kidney di...

Tens of thousands of people with chronic kidney disease in England could be eligible for treatment with AstraZeneca's SGLT2 inhibitor Forxiga, after NICE backed NHS use of the drug in draft

NICE backs Biogen's Vumerity for multiple sclerosis

Drugmakers pledge shorter launch times for drugs in EU

NICE verdict on Trodelvy threatens unequal access to drug in...

NHS grants fast-track access to Takeda's lung cancer drug Ex...

Moderna squares off with US government over COVID jab patent

Cautious welcome as NICE backs Forxiga for chronic kidney di...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

access

Editor's Picks